Imaging Synapses With [11C] UCB-J in the Human Brain

ConditionSchizophrenia
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorDavidzon, Guido, M.D.

About this trial

The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer \[11C\]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. This imaging method allows for the quantification of synaptic density in the living human brain and has the unprecedented ability to directly examine the synaptic pathology underlying neuropsychiatric disease. The neural synaptic pruning hypothesis posits that a key pathogenic process of schizophrenia is the over-exuberant elimination of neural synapses during development. The confirmation of reduced synaptic density in schizophrenia as evidenced by \[11C\]UCB-J has the potential to lead to a number of ground-breaking clinical innovations, such as laboratory-based diagnostics and prognostics, and novel, disease-modifying treatments.

Eligibility criteria

Qualifiers

18 - 65 years in age

On a stable medication regimen for at least two weeks prior to testing

A clinical diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder

Able to complete a PET-MR scan without the use of sedation

Disqualifiers

Active substance use within three months of testing

IQ < 70

Major medical neurological illness or significant head trauma

Pregnancy or breastfeeding

Trial design

Treatments tested in this trial

  • [11C]UCB-J radiotracer
  • PET-MR

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Davidzon, Guido, M.D.

Lead sponsor

Stanford University

Sponsor institution

Weston Havens Foundation

Collaborator